Future CNS Clinical Development Driven by Market Access Evaluation: The Payer Centric Approach

LONDON - May 27, 2013 - PRLog -- Future CNS Clinical Development Programs have to be directly linked to the evolving CNS drug market where the patient effectively makes the decision about their health. By adjusting and becoming patient-centric, physicians can target specific clinical needs and help providers treat individual patients, in turn this will help save time and costs. However demonstrating clinical relevant efficacy and effectiveness is often a difficult task, especially in CNS.

Against this backdrop, SMi's masterclass will discuss how a 'Payer Centric Approach' can drive Future CNS Clinical Development and how innovative techniques and superiority concepts - validated by in depth market access evaluation can lead to successful new CNS therapeutics.

Benefits of Attending
• Get an insight in the real drivers of the future CNS clinical development programs and related opportunities
• Learn how 'Superiority' is the new objective for future CNS clinical development
• Identify the key driving factors for having a real chance on the CNS market place dominated by the payers
• Work with your peers on how new techniques and concepts can creat a major opportunity in the main CNS domains: Depression, Schizophrenia and Alzheimers Disease

For more information, visit: www.smi-online.co.uk/cns-development14.asp
Contact Jonathan Collins on +44 (0) 20 7827 6734 or jcollins@smi-online.co.uk

####

About the host

Dr. Buntinx is a qualified psychiatrist, inventor, developer of several CNS drugs and former founder and CEO of the CNS specialty company PharmaNeuroBoost in which role he raised E25million. Dr. Buntinx has achieved worldwide nine granted patents and previously founded the Anima Center, an outpatient psychiatric clinic and integrated clinical research unit. Dr. Buntinx was the first to achieve support from the FDA for a pivotal trial that used a new endpoint demonstrating superior efficacy over standard of care in major depression: ESR (Early and Sustained Response Rate). Dr. Buntinx, driven by the spirit of his mentor Dr. Paul Janssen, is a frequently invited speaker in relation to his CNS and clinical development expertise.